MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12369-12378

  Zhou, Yanqi ^a   Chen, Qiaoyun ^a   Qin, Rong ^a   Zhang, Kaifeng ^a   Li, Hao ^b  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b TAIXING PEOPLE'S HOSPITAL   (China)

Author keywords

Cisplatin resistance; MicroRNA 449a; NOTCH1; Ovarian cancer

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 449A; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; MIRN449 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; MTT ASSAY; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BINDING SITE; CHEMISTRY; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; OVARIAN NEOPLASMS; RECEPTOR, NOTCH1; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925283931     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2551-3     Document Type: Article

References (33)

1. Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435:188–94.
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu. 2013;25:10–21.
3. Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu. 2012;24:171–80.
4. Januchowski R, Zawierucha P, Rucinski M, Nowicki M, Zabel M. Extracellular matrix proteins expression profiling in chemoresistant variants of the a2780 ovarian cancer cell line. BioMed Res Int. 2014;2014:365867.
5. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist updat: Rev Commentaries Antimicrob Anticancer Chemother. 2002;5:147–61.
6. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat: Rev Commentaries Antimicrob Anticancer Chemother. 2003;6:169–72.
7. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
9. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100:9779–84.
10. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res: CR. 2011;30:55.
11. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.
12. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.
13. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011;124:359–68.
14. Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic bcl-2 antagonist killer 1. J Huazhong Univ Sci Technol Med Sci = Hua zhong Ke Ji Da Xue Xue Bao Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 2011;31:543–9.
15. Wu H, Xiao Z, Zhang H, Wang K, Liu W, Hao Q. miR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anti-cancer Drugs 2014.
16. Wei B, Song Y, Zhang Y, Hu M. MicroRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett. 2013;6:1713–8.
17. Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, et al. Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells. Cancer Lett. 2014;344:195–203.
18. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012;586:1279–86.
19. Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, et al. Plexin-b1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 2011;43:632–41.
20. Capuano M, Iaffaldano L, Tinto N, Montanaro D, Capobianco V, Izzo V, et al. MicroRNA-449a overexpression, reduced NOTCH1 signals and scarce goblet cells characterize the small intestine of celiac patients. PLoS One. 2011;6:e29094.
21. Lize M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2010;17:452–8.
22. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28:1714–24.
23. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 2011;10:29.
24. Chen H, Lin YW, Mao YQ, Wu J, Liu YF, Zheng XY, et al. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett. 2012;320:40–7.
25. Hu J, Fang Y, Cao Y, Qin R, Chen Q. miR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 2014;59:336–45.
26. Dang TP. Notch, apoptosis and cancer. Adv Exp Med Biol. 2012;727:199–209.
27. Geissler K, Zach O. Pathways involved in drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway. Ann Hematol. 2012;91:645–69.
28. Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol. 2012;727:186–98.
29. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73:406–16.
30. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012;109:E2939–48.
31. Kofler NM, Shawber CJ, Kangsamaksin T, Reed HO, Galatioto J, Kitajewski J. Notch signaling in developmental and tumor angiogenesis. Genes Cancer. 2011;2:1106–16.
32. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6:e21121.
33. Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014;444:670–5.